Cart
×
Avidity Biosciences Webinar: EXPLORE44
A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping
Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and Mark Stahl from Avidity Biosciences for a presentation and discussion on the EXPLORE44TM clinical trial. EXPLORE44 is a Phase 1/2 clinical trial evaluating AOC 1044 for the treatment of individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44). AOC 1044 is an antibody oligonucleotide conjugate (AOCTM) and is designed to use an antibody to deliver an exon 44-skipping oligonucleotide to muscle and heart cells. AOC 1044 is the first of multiple AOCs Avidity is developing for the Duchenne community.
Speakers
Kelly DiTrapani, RN, BSN, BA
Vice President, Medical Affairs
In September of 2020, Kelly DiTrapani joined Avidity as Vice President of Medical Affairs. Kelly brings extensive commercial and medical affairs leadership in the life sciences industry, focused on bringing innovative therapeutics to patients in the oncology and rare disease spaces including Gleevec, Soliris and Imbruvica. Throughout her career, Kelly has held positions in industry and academics across roles in research, commercial and medical affairs at Ortho Biotech (J&J), Novartis Oncology, Duke University, Alexion Pharmaceuticals, Pharmacyclics, Versartis and Iovance Biotherapeutics.
Kelly received both her Bachelor of Arts and Bachelor of Science in Nursing from Duke University.
Mark Stahl, MD, PhD
Senior Director, Clinical Development
Mark joined Avidity as Senior Medical Director in March of 2021. Most recently he served as Medical Director in Early Clinical Development at Neurocrine Biosciences, where he worked on multiple preclinical and clinical stage programs including the initiation of new gene therapy programs in rare diseases. Previously, Mark worked as an Assistant Professor at Penn State University, where he founded a research laboratory focused on modeling neurodegenerative diseases, was associate director of the university’s Medical Scientist Training Program and maintained an active clinical practice in neurology. Mark holds an M.D. degree from the Albert Einstein College of Medicine and completed both residency in neurology and fellowship training in movement disorders at UCLA. He holds a Ph.D. in cell biology, also from the Albert Einstein College of Medicine, and completed his postdoctoral research fellowship training in neuroscience at UCLA.
